PL367628A1 - Zastosowanie alkanoilo L-karnityny do sporządzenia leku mającego zastosowanie w leczenia anhedonii - Google Patents

Zastosowanie alkanoilo L-karnityny do sporządzenia leku mającego zastosowanie w leczenia anhedonii

Info

Publication number
PL367628A1
PL367628A1 PL02367628A PL36762802A PL367628A1 PL 367628 A1 PL367628 A1 PL 367628A1 PL 02367628 A PL02367628 A PL 02367628A PL 36762802 A PL36762802 A PL 36762802A PL 367628 A1 PL367628 A1 PL 367628A1
Authority
PL
Poland
Prior art keywords
carnitine
alkanoyl
preparation
medication
anhedonia
Prior art date
Application number
PL02367628A
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2001RM000292A external-priority patent/ITRM20010292A1/it
Priority claimed from IT2001RM000319A external-priority patent/ITRM20010319A1/it
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of PL367628A1 publication Critical patent/PL367628A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL02367628A 2001-05-29 2002-05-24 Zastosowanie alkanoilo L-karnityny do sporządzenia leku mającego zastosowanie w leczenia anhedonii PL367628A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001RM000292A ITRM20010292A1 (it) 2001-05-29 2001-05-29 Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia.
IT2001RM000319A ITRM20010319A1 (it) 2001-06-08 2001-06-08 Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia.
PCT/IT2002/000339 WO2002096411A1 (en) 2001-05-29 2002-05-24 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Publications (1)

Publication Number Publication Date
PL367628A1 true PL367628A1 (pl) 2005-03-07

Family

ID=26332845

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367628A PL367628A1 (pl) 2001-05-29 2002-05-24 Zastosowanie alkanoilo L-karnityny do sporządzenia leku mającego zastosowanie w leczenia anhedonii

Country Status (16)

Country Link
US (2) US20040171685A1 (pl)
EP (1) EP1399143B1 (pl)
JP (1) JP2004532867A (pl)
KR (1) KR20040003031A (pl)
AT (1) ATE345124T1 (pl)
CA (1) CA2448246A1 (pl)
CZ (1) CZ20033222A3 (pl)
DE (1) DE60216090T2 (pl)
DK (1) DK1399143T3 (pl)
ES (1) ES2275881T3 (pl)
HU (1) HUP0400007A2 (pl)
MX (1) MXPA03010920A (pl)
PL (1) PL367628A1 (pl)
PT (1) PT1399143E (pl)
SK (1) SK15862003A3 (pl)
WO (1) WO2002096411A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
WO2023084531A1 (en) * 2021-11-12 2023-05-19 Celagenex Research (India) Pvt. Ltd. A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1291930B1 (it) * 1997-06-18 1999-01-21 Sigma Tau Ind Farmaceuti Composizione riequilibratrice delle turbe dell'umore in individui sani

Also Published As

Publication number Publication date
PT1399143E (pt) 2007-01-31
DE60216090T2 (de) 2007-05-31
CA2448246A1 (en) 2002-12-05
ATE345124T1 (de) 2006-12-15
KR20040003031A (ko) 2004-01-07
US20060148896A1 (en) 2006-07-06
US20040171685A1 (en) 2004-09-02
DE60216090D1 (de) 2006-12-28
EP1399143B1 (en) 2006-11-15
JP2004532867A (ja) 2004-10-28
ES2275881T3 (es) 2007-06-16
CZ20033222A3 (cs) 2004-06-16
EP1399143A1 (en) 2004-03-24
DK1399143T3 (da) 2007-03-26
HUP0400007A2 (hu) 2004-04-28
WO2002096411A1 (en) 2002-12-05
MXPA03010920A (es) 2004-02-27
SK15862003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
MXPA03007712A (es) Sales farmaceuticas.
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2003080582A3 (de) Fredericamycin-derivate
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
AU5372199A (en) Cyclopentabenzofuran derivatives and their use
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
PL367616A1 (pl) Zastosowanie acetylo-L-karnityny do otrzymywania leku do terapii przeciwbólowej
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
SI1458376T1 (sl) Darifenacin za uporabo pri zdravljenju nuje, ki je posledica prekomerno aktivnega sečnega mehurja
WO2002089848A3 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
IL149160A0 (en) Use of 2-amino-3, 4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions
IL160486A0 (en) Citalopram for the treatment of elevated blood pressure
MY124089A (en) Use of cetirizine for preventing the onset of asthma
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
AU4485101A (en) Antiviral therapy
AU2002359762A1 (en) Luminacin analogs and uses thereof
SI1817029T1 (sl) Derivati izoksazola za lajĺ anje nevropatskih boleäśin
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)